Replies to post #25327 on Rebus Holdings Inc (RBSH)

[powerbattles]

The delay phase 3 mainly cause by lack of the supplier compound chemically-derived thapsigargin. This this is the biggest problem to why they can't move to phase3.

In order to find a solution they partnership with Phyton Biotech. Inspyr Therapeutics partnership with Phyton Biotech has begun development program converting the Thapsia garganic plant into thapsigargin.

https://phytonbiotech.com/phyton-biotech-achieves-manufacturing-milestone-with-thapsigargin-the-active-agent-in-mipsagargin/

Inspyr Therapeutics has a patented technology platform utilizing thapsigargin for its prodrug mipsagargin G-202

Phyton Biotech they work with a lot of big Pharma players and this company is an expert in the field. IMO: A possible partnership/buyout could be in the making through Phyton Biotech.